Liu Nick W, Wren James D, Vertosick Emily, Lee Justin K, Power Nicholas E, Benfante Nicole E, Kimm Simon Y, Bains Manjit S, Sjoberg Daniel D, Russo Paul, Coleman Jonathan A
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
J Urol. 2016 Feb;195(2):264-9. doi: 10.1016/j.juro.2015.08.099. Epub 2015 Sep 10.
We examined the impact of positive vascular margins in patients with pT3 clear cell renal cell carcinoma.
After excluding patients with nonvascular positive margins, metastasis, lymph node involvement, neoadjuvant therapy or nonclear cell histology, we identified 224 patients with venous tumor invasion through our institutional database from 1999 to 2013. Kaplan-Meier analysis and log rank tests were used to evaluate whether positive vascular margins were associated with progression-free survival or cancer specific survival.
There were 41 patients (18%) with a positive vascular margin. Margin status was directly related to the level of invasion (p <0.0001). Compared to the negative vascular margin group the positive group had a significantly worse progression-free survival (p=0.01) but not cancer specific survival (p=0.3). Similarly the level of vascular thrombus invasion was significantly associated with worse progression-free survival (p=0.02) but not cancer specific survival (p=0.4). The 3-year progression-free survival was worst with inferior vena cava invasion and best with segmental/muscular venous branch invasion (54%, 95% CI 34-70 vs 76%, 95% CI 64-85). Among patients with only main renal vein thrombus, vascular margin status was not associated with progression-free survival (p=0.5) or cancer specific survival (p=0.2).
In patients with pT3N0/XM0 clear cell renal cell carcinoma positive vascular margins are associated with risk of disease progression. However, the risk of relapse associated with positive vascular margins is driven by the extent of vascular thrombus invasion. These findings suggest that the clinical significance of vascular margin status as currently defined in pT3 clear cell renal cell carcinoma is minimal.
我们研究了pT3期透明细胞肾细胞癌患者中阳性血管切缘的影响。
在排除具有非血管阳性切缘、转移、淋巴结受累、新辅助治疗或非透明细胞组织学的患者后,我们通过机构数据库从1999年至2013年确定了224例有静脉肿瘤侵犯的患者。采用Kaplan-Meier分析和对数秩检验来评估阳性血管切缘是否与无进展生存期或癌症特异性生存期相关。
有41例患者(18%)存在阳性血管切缘。切缘状态与侵犯程度直接相关(p<0.0001)。与阴性血管切缘组相比,阳性组的无进展生存期明显更差(p=0.01),但癌症特异性生存期无差异(p=0.3)。同样,血管血栓侵犯程度与更差的无进展生存期显著相关(p=0.02),但与癌症特异性生存期无关(p=0.4)。3年无进展生存期在下腔静脉侵犯时最差,在节段性/肌性静脉分支侵犯时最佳(54%,95%CI 34-70 vs 76%,95%CI 64-85)。在仅存在主肾静脉血栓的患者中,血管切缘状态与无进展生存期(p=0.5)或癌症特异性生存期(p=0.2)无关。
在pT3N0/XM0期透明细胞肾细胞癌患者中,阳性血管切缘与疾病进展风险相关。然而,与阳性血管切缘相关的复发风险是由血管血栓侵犯的程度驱动的。这些发现表明,目前在pT3期透明细胞肾细胞癌中定义的血管切缘状态的临床意义很小。